Palynziq (pegvaliase-pqpzl) for phenylketonuria (PKU)
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.63 alerts
Get alerted when Policy 05.02.63 changes without checking for updates manually.
Monitor payer policy activity
Coverage criteria and prior authorization requirements for Palynziq (pegvaliase-pqpzl) for treatment of phenylketonuria in members of Wellmark/Blue Cross Blue Shield plans where benefits apply.
Updated policy effective date and revised clinical/coverage criteria for Palynziq (pegvaliase-pqpzl).
Coverage Criteria for Palynziq (pegvaliase-pqpzl)
Initial Approval Criteria
Covered when ALL of the following are met:
Items 5 and 6 explicitly prohibit concomitant use of sapropterin or sepiapterin.
Continuation of Therapy — Responder
Covered when ALL of the following are met:
Continuation requires both biochemical response and clinical improvement or stabilization.
Continuation of Therapy — Nonresponder / Titration
OR — when the member has not met the responder criteria, approval may be granted if the following are met:
Approval in this scenario will be for 6 months to allow titration to 60 mg/day; FDA label supports up to 60 mg daily.
Coverage considerations from clinical trials and label
Evidence-based considerations from PRISM trials and labeling:
Randomized discontinuation enrolled patients stable on pegvaliase with prior ≥20% Phe reduction.
Greater change observed in patients with baseline ADHD RS-IV IA >9.
REMS and counseling required due to anaphylaxis risk.
Consider documenting dose escalations and justification when exceeding 40 mg up to 60 mg.
Palynziq (pegvaliase-pqpz) is considered not medically necessary for members who do not meet the coverage criteria set forth in this policy. Members who are currently receiving Palynziq as samples or through the manufacturer's patient assistance program must still meet the documented initial approval criteria to be eligible for continued coverage, ensuring consistent treatment decisions regardless of how the medication was obtained.
No explicit exclusions beyond the stated coverage criteria are identified in this segment of the policy. The document does not list separate disease states, concomitant therapies, or patient subgroups that are categorically excluded from consideration beyond the requirement to meet the specified approval criteria.
If the member does not satisfy the required initial or continuation criteria described in this policy, Palynziq is considered not medically necessary. Requests that lack adequate documentation demonstrating the criteria have been met (for example, required baseline or follow-up blood phenylalanine values or specialist consultation) may be denied on that basis.
While neuropsychiatric and neurocognitive measures were assessed in clinical studies and improvements were reported at later time points, the policy does not define absence of neuropsychiatric improvement as a standalone coverage denial criterion. Continuation decisions require both biochemical response and assessment of clinical status per the stated continuation criteria; neuropsychiatric changes are considered as part of overall clinical response but are not separately specified as an exclusion.
Procedures, Codes, and Key Clinical Thresholds
| unlisted / J-codes not specified | Policy references use of appropriate CPT, HCPCS, Revenue, and ICD diagnostic codes; no specific codes listed in this part of document. |
Prior Authorization, Documentation, and REMS Requirements
Prior authorization required — submit medical records and confirm prescriber specialty
Submit complete medical records to support prior authorization: chart notes and laboratory values documenting baseline blood phenylalanine >600 μmol/L despite dietary restriction and use of a sapropterin product, documentation that Palynziq will not be used concomitantly with a sapropterin product or Sephience (sepiapterin) or documentation that these will be discontinued after an appropriate overlap, and that the prescriber is a metabolic disease/PKU specialist or consulting one for initial approvals.
- Medical records (chart notes, laboratory values) documenting baseline blood Phe >600 μmol/L despite dietary Phe restriction and a sapropterin product
- Records documenting response to therapy per continuation criteria with blood Phe values
- Documentation that Palynziq will not be used with sapropterin or Sephience or will be discontinued after appropriate overlap
- Prescribed by or in consultation with a metabolic disease/PKU specialist (initial approvals)
Confirm REMS enrollment and justify dosing (including use of 60 mg)
Prior authorization must confirm enrollment/certification in the Palynziq REMS program and provide dosing justification, including justification for escalation up to 60 mg when clinically required.
- Confirm prescriber, patient, and dispensing pharmacy REMS certification/enrollment
- Provide justification for use of doses above 40 mg up to 60 mg when clinically required
Step therapy — document prior sapropterin trial or intolerance; prohibit concomitant sapropterin/Sephience
Member must have had an inadequate response, intolerance, or clinical reason to avoid a sapropterin product before Palynziq is approved; Palynziq must not be used concurrently with sapropterin products or Sephience.
- Document inadequate response, intolerance, or clinical reason to avoid sapropterin
- Confirm Palynziq will not be used in combination with sapropterin products or Sephience (sepiapterin)
Step considerations — document prior response and allow titration time before higher maintenance dose
Consider trial design and dosing history when authorizing higher maintenance doses; document prior adequate response or attempt lower doses and allow titration time (approval for 6 months when titrating to 60 mg/day).
- PRISM-2 randomized discontinuation context supports documenting prior response on lower doses before increasing
- If not yet titrated to 60 mg once daily or <16 weeks at max dose, approval may be for 6 months to allow titration
Required documentation — baseline and follow-up Phe values and chart notes
Provide medical records/chart notes and laboratory values documenting baseline blood phenylalanine >600 μmol/L despite dietary restriction and sapropterin, and blood Phe values per continuation criteria to demonstrate response or need for ongoing titration.
- Baseline blood Phe >600 μmol/L documented despite dietary Phe restriction and sapropterin
- Blood Phe values showing clinical response (≤600 μmol/L) or documentation of titration status if not yet at max dose
- Chart notes supporting clinical improvement or stabilization (neurocognitive/neuropsychiatric) for continuation
Required clinical and REMS documentation — REMS enrollment, epinephrine, counseling, dose justification
Document REMS certification/enrollment for prescriber, patient, and dispensing pharmacy; record that auto-injectable epinephrine was prescribed and is available to the patient; document counseling on anaphylaxis recognition/response and any dose escalations/justification.
- REMS certification/enrollment for prescriber, patient, and dispensing pharmacy
- Prescription and patient possession of auto-injectable epinephrine
- Documentation of counseling on recognizing and responding to anaphylaxis
- Record dose escalations and justification if doses above 40 mg up to 60 mg are used
Denial risk — requests considered not medically necessary if criteria not met
Requests lacking required clinical criteria or documentation will be considered not medically necessary and may be denied — members must meet initial or continuation criteria for coverage.
- Failure to meet initial approval criteria (e.g., diagnosis, age ≥12, baseline Phe >600 μmol/L despite management, specialist involvement) may render the request not medically necessary
- Failure to meet continuation criteria (clinical response or allowed titration conditions) may render ongoing treatment not medically necessary
Denial risk — REMS enrollment or epinephrine documentation missing
Failure to document REMS enrollment/certification, lack of prescription or documentation that the patient has auto-injectable epinephrine, or absence of counseling on anaphylaxis recognition/response may trigger denial or prior authorization failure.
- Missing REMS enrollment/certification for prescriber, patient, or pharmacy
- No prescription or evidence patient possesses auto-injectable epinephrine
- No documentation of counseling on anaphylaxis recognition and response
Background on Phenylketonuria and Treatment Context
Phenylketonuria (PKU) is an inherited metabolic disorder in which deficient phenylalanine metabolism leads to chronically elevated blood and brain phenylalanine (Phe) concentrations with potential neurocognitive and psychiatric sequelae. Management centers on lifelong dietary Phe restriction and medical food; the goal recommended by guidelines is maintaining blood Phe in the target range (ACMG: 120–360 μmol/L). Palynziq (pegvaliase-pqpzl) is a biologic therapy indicated for patients aged ≥ 12 years with uncontrolled blood Phe despite existing management and typically requires gradual dose escalation (titration may take many weeks) to reach maintenance doses up to 60 mg once daily; treatment carries a significant hypersensitivity risk including anaphylaxis and is available only through a REMS program that requires prescriber/patient/pharmacy enrollment and prescription of auto-injectable epinephrine.
Key Definitions and Trial Descriptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.